These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 3918556)

  • 1. The effect of 1-deamino 8 D-arginine vasopressin (DDAVP) in a nonhaemophilic patient with an acquired type II factor VIII inhibitor.
    de la Fuente B; Panek S; Hoyer LW
    Br J Haematol; 1985 Jan; 59(1):127-31. PubMed ID: 3918556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1-Deamino-8-D-arginine vasopressin in the treatment of non-haemophilic patients with acquired factor VIII inhibitor.
    Muhm M; Grois N; Kier P; Stümpflen A; Kyrle P; Pabinger I; Bettelheim P; Hinterberger W; Lechner K
    Haemostasis; 1990; 20(1):15-20. PubMed ID: 2108912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of 1-deamino-8-D-arginine vasopressin on the prolonged bleeding time in chronic renal failure.
    Watson AJ; Keogh JA
    Nephron; 1982; 32(1):49-52. PubMed ID: 6817151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DDAVP in a non-haemophiliac patient with an acquired factor VIII inhibitor.
    Vincente V; Alberca I; Gonzalez R; Lopez Borrasca A
    Br J Haematol; 1985 Jul; 60(3):585-6. PubMed ID: 3925984
    [No Abstract]   [Full Text] [Related]  

  • 5. Properties of the factor VIII after DDAVP (1-deamino-8-D-arginine vasopressin) infusion in normal subjects.
    Takahashi H; Itoh M; Kobayashi I; Sakuragawa N; Shibata A
    Tohoku J Exp Med; 1980 Oct; 132(2):133-40. PubMed ID: 6777902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The effect of 1-deamino-8-D-arginine vasopressin (DDAVP) on blood coagulation in patients with hemophilia A and in healthy men].
    Blättler W; Jacky E; Müller M; Graf M
    Schweiz Med Wochenschr; 1979 Sep; 109(37):1367-8. PubMed ID: 314661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DDAVP: a useful alternative to blood components in moderate hemophilia A and von Willebrand disease.
    Warrier AI; Lusher JM
    J Pediatr; 1983 Feb; 102(2):228-33. PubMed ID: 6401806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DDAVP in acquired hemophilia A: case report and review of the literature.
    Mudad R; Kane WH
    Am J Hematol; 1993 Aug; 43(4):295-9. PubMed ID: 8372811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [DDAVP and its effect on factor VIII activity (author's transl)].
    Sikorová J; Vorlová Z
    Cas Lek Cesk; 1981 May; 120(18):553-6. PubMed ID: 6794913
    [No Abstract]   [Full Text] [Related]  

  • 10. Factor VII and fibrinolytic response to deamino-8-D-argenine vasopressin in normal subjects and dissociate response in some patients with haemophilia and von Willebrand's disease.
    Ludlam CA; Peake IR; Allen N; Davies BL; Furlong RA; Bloom AL
    Br J Haematol; 1980 Jul; 45(3):499-511. PubMed ID: 6775673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Response to DDAVP in von Willebrand disease type II C].
    Batllé Fonrodona J; López Fernández MF; Martín González R; Fernández Villamor A; López Borrasca A; Lasierra Cirujeda J
    Sangre (Barc); 1985; 30(2):181-4. PubMed ID: 3925573
    [No Abstract]   [Full Text] [Related]  

  • 12. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia.
    Mannucci PM; Remuzzi G; Pusineri F; Lombardi R; Valsecchi C; Mecca G; Zimmerman TS
    N Engl J Med; 1983 Jan; 308(1):8-12. PubMed ID: 6401193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experience with deamino-8-D-AGR-Vasopressin (DDAVP) in patients with Factor VIII deficiency.
    Sweeney JD; Crosby P; McCann SR; Temperley IJ
    Ir J Med Sci; 1981 Aug; 150(8):236-9. PubMed ID: 6974718
    [No Abstract]   [Full Text] [Related]  

  • 14. Response of factor XII to DDAVP in patients with Hageman factor deficiency.
    Gamba G; Grignani G; Longoni P; Ascari E
    Br J Haematol; 1983 Dec; 55(4):713-5. PubMed ID: 6422975
    [No Abstract]   [Full Text] [Related]  

  • 15. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitor to factor VIII in a non-haemophilic patient: evaluation of the response to DDAVP and the in vitro kinetics of factor VIII. A case report.
    Chistolini A; Ghirardini A; Tirindelli MC; Moretti T; Mancini F; Di Paolantonio T; Mariani G
    Nouv Rev Fr Hematol (1978); 1987; 29(4):221-4. PubMed ID: 3122176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factor VIII-related activities after 1-deamino-8-D-arginine vasopressin in multicentric reticulohistiocytosis.
    Taddeo U; Trotta F; Menegale G; Ballerini G
    Ric Clin Lab; 1984; 14(1):37-9. PubMed ID: 6427880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Normal response of factor VIII and von Willebrand factor to 1-deamino-8D-arginine vasopressin in nephrogenic diabetes insipidus.
    Brenner B; Seligsohn U; Hochberg Z
    J Clin Endocrinol Metab; 1988 Jul; 67(1):191-3. PubMed ID: 3132483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The position of a vasopressin derivative ("DDAVP") in the treatment of haemophilia A (author's transl)].
    Blättler W; Jacky E; Müller M; Graf M; Meili E
    Ther Umsch; 1979 Apr; 36(4):330-3. PubMed ID: 377557
    [No Abstract]   [Full Text] [Related]  

  • 20. Effectiveness, specificity and safety of intranasal 1-deamino-8-D-arginine vasopressin treatment of normal blood donors.
    Palmer DS; Harris AS; Tittley P; Rock G
    Haemostasis; 1988; 18(3):187-96. PubMed ID: 2972594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.